Reinhard Dummer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint From chemotherapy to targeted treatment
    R Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Ann Oncol 23:x101-3. 2012
  2. ncbi request reprint Role of imiquimod in skin cancer treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Am J Clin Dermatol 5:453-8. 2004
  3. doi request reprint The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
    Reinhard Dummer
    UniversitätsSpital Zürich Skin Cancer Center, University Hospital, Zurich, Switzerland Electronic address
    J Am Acad Dermatol 75:113-125.e5. 2016
  4. ncbi request reprint External beam radiotherapy of extramammary Paget disease
    Selma Tackenberg
    Department of Derma Gloriastrasse 31, CH 8091, Zurich, Switzerland
    Cutis 95:109-12. 2015
  5. doi request reprint Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)
    R Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Ann Oncol 25:1807-12. 2014
  6. pmc Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
    Nathalie Accart
    Transgene S, A, Boulevard Gonthier d Andernach, Parc d Innovation, 67405 Cedex Illkirch Graffenstaden, France
    J Transl Med 11:226. 2013
  7. pmc Long-term pegylated interferon-alpha and its potential in the treatment of melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Biologics 3:169-82. 2009
  8. doi request reprint Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Electronic address
    Eur J Cancer 50:611-21. 2014
  9. doi request reprint Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Clin Oncol 30:4091-7. 2012
  10. doi request reprint Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
    Reinhard Dummer
    University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
    Leuk Lymphoma 53:1501-8. 2012

Detail Information

Publications180 found, 100 shown here

  1. ncbi request reprint From chemotherapy to targeted treatment
    R Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Ann Oncol 23:x101-3. 2012
    ..after this first progress in the treatment of advanced melanoma, there is expectation that combinations of kinase inhibitor will additionally improve the overall survival rates and progression-free survival in advanced melanoma...
  2. ncbi request reprint Role of imiquimod in skin cancer treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Am J Clin Dermatol 5:453-8. 2004
    ..This article reviews current literature on the use of imiquimod in the treatment of nonmelanoma and melanoma skin cancer...
  3. doi request reprint The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
    Reinhard Dummer
    UniversitätsSpital Zürich Skin Cancer Center, University Hospital, Zurich, Switzerland Electronic address
    J Am Acad Dermatol 75:113-125.e5. 2016
    ..The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study...
  4. ncbi request reprint External beam radiotherapy of extramammary Paget disease
    Selma Tackenberg
    Department of Derma Gloriastrasse 31, CH 8091, Zurich, Switzerland
    Cutis 95:109-12. 2015
    ..An effective alternative is external beam radiotherapy (EBRT), which typically results in rapid resolution of EMPD. In this study, we analyzed long-term outcomes in 7 patients who were treated with EBRT for EMPD. ..
  5. doi request reprint Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)
    R Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Ann Oncol 25:1807-12. 2014
    ..Forodesine has demonstrated impressive antitumor activity in early phase clinical trials in cutaneous T-cell lymphoma (CTCL)...
  6. pmc Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042
    Nathalie Accart
    Transgene S, A, Boulevard Gonthier d Andernach, Parc d Innovation, 67405 Cedex Illkirch Graffenstaden, France
    J Transl Med 11:226. 2013
    ....
  7. pmc Long-term pegylated interferon-alpha and its potential in the treatment of melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Biologics 3:169-82. 2009
    ..Ongoing research must focus on the identification of patients who mostly benefit, so that unnecessary toxicity would be avoided. Combining PegIFNs and chemotherapy or targeted agents deserves further exploration...
  8. doi request reprint Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Electronic address
    Eur J Cancer 50:611-21. 2014
    ..Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase inhibitor vemurafenib in patients with advanced melanoma with symptomatic brain metastases...
  9. doi request reprint Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Clin Oncol 30:4091-7. 2012
    ..There is a need for multicenter trials involving defined patient populations using rigorous assessment criteria. We have investigated pegylated liposomal doxorubicin (PLD) in a clearly defined patient population with advanced MF...
  10. doi request reprint Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition
    Reinhard Dummer
    University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
    Leuk Lymphoma 53:1501-8. 2012
    ..We conclude that concomitant administration of vorinostat and bexarotene is feasible only if lower doses of each drug are administered relative to the product label monotherapy doses...
  11. doi request reprint [Therapeutic approaches in Melanoma - a paradigm for personalized medicine]
    R Dummer
    Dermatologische Klinik, Universitatsspital Zurich
    Praxis (Bern 1994) 101:955-9. 2012
    ..These developments are the first steps resulting in a personalized treatment approach for individuals affected by melanoma...
  12. doi request reprint Cutaneous lymphomas: molecular pathways leading to new drugs
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Invest Dermatol 132:517-25. 2012
    ..The rational and well-coordinated application of these tools, together with improved chemotherapeutic options, will hopefully further improve treatment success in the near future...
  13. doi request reprint Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Curr Opin Oncol 24:150-4. 2012
    ..After years of therapeutic approaches with limited effects in metastatic melanoma, new inhibitors of serine-threonine and tyrosine kinases have demonstrated impressive clinical efficacy and improved survival...
  14. doi request reprint Sorafenib in melanoma
    Joanna Mangana
    University Hospital of Zurich, Department of Dermatology, Gloriastrasse 31, Zurich, 8091, Switzerland
    Expert Opin Investig Drugs 21:557-68. 2012
    ..The drug is well tolerated with mild to moderate adverse effects, which are mostly limited to cutaneous toxicity, diarrhea and fatigue...
  15. ncbi request reprint [Cutaneous neoplasms]
    R Dummer
    Dermatologische Klinik, Universitatsspital Zurich
    Praxis (Bern 1994) 92:1470-8. 2003
    ..Since the majority of malignant neoplasms is removable and curable by a simple surgical intervention, the knowledge of the different skin tumors is essential for non-dermatologist...
  16. ncbi request reprint Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Blood 104:1631-8. 2004
    ..We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated...
  17. ncbi request reprint Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Dermatology 210:39-44. 2005
    ..New data necessitated changes concerning the safety margins (reduction to maximally 2 cm) and modifications of the recommendations of follow-up...
  18. ncbi request reprint Emerging drugs in cutaneous T-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Expert Opin Emerg Drugs 10:381-92. 2005
    ....
  19. ncbi request reprint Standard and experimental therapy in cutaneous T-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Cutan Pathol 33:52-7. 2006
    ..Evidence-based treatment recommendation exists but is hampered by the lack of large multicenter randomized trials...
  20. ncbi request reprint Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Clin Oncol 24:1188-94. 2006
    ..This open-label, randomized study evaluated the safety, tolerability, and efficacy of subcutaneous PEG-IFNalpha-2a in patients with metastatic malignant melanoma (stage IV American Joint Committee on Cancer staging system)...
  21. ncbi request reprint Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Semin Oncol 33:S26-32. 2006
    ..This article provides details of five real-life case studies to illustrate how cutaneous T-cell lymphoma management can be tailored to the needs of each individual patient...
  22. ncbi request reprint Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL)
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Semin Oncol 33:S33-6. 2006
    ..Other identified agents include vaccines and monoclonal antibodies. This article reviews some of the most recent clinical innovations...
  23. ncbi request reprint Elastosis colloidalis conglomerata (adult colloid milium, paracolloid of the skin): a maximal manifestation of actinic elastosis?
    Reinhard Dummer
    University Hospital of Zurich, Department of Dermatology, Gloriastrasse 31, 8091 Zurich, Switzerland
    Eur J Dermatol 16:163-6. 2006
    ..Histology revealed elastosis colloidalis conglomerata. There were no hints for a deposition disease. The patient was treated with local retinoids. We report on the therapeutic outcome...
  24. ncbi request reprint Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 15:392-400. 2006
    ....
  25. ncbi request reprint [Perspective of cutaneous lymphoma reserach]
    Reinhard Dummer
    Dermatologische Klinik, Universitatsspital Zurich, Schweiz
    J Dtsch Dermatol Ges 4:492-5. 2006
    ..The new WHO/EORTC classification definitely will facilitate a more detailed investigation of the various subtypes...
  26. ncbi request reprint Cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University of Zurich, Switzerland
    J Dtsch Dermatol Ges 5:605-17. 2007
    ..Treatment is dependent on stage. As complete cure is not possible, it is essential to control the disease and alleviate symptoms. In recent years numerous new drugs have been developed to treat these diseases...
  27. ncbi request reprint Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Eur J Cancer 43:2321-9. 2007
    ..Of the systemic therapies currently approved for the treatment of CTCL, bexarotene and IFN-alpha are obvious candidates for testing, because they can be self-administered by the patient and provide good long-term tolerability...
  28. ncbi request reprint Recent advances in cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    J Dermatol Sci 48:157-67. 2007
    ....
  29. doi request reprint An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 14:856-64. 2008
    ..A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, in patients with metastatic melanoma...
  30. doi request reprint Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Mol Ther 16:985-94. 2008
    ..Our results show that intratumoral injections of TG1024 are safe and well tolerated. The clinical activity of TG1024 observed in this study warrants further investigations...
  31. pmc Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Mol Ther 18:1244-7. 2010
    ..CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy...
  32. doi request reprint Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
    R Dummer
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Swiss Med Wkly 141:w13320. 2011
    ..A new classification and recent results in randomised trials necessitated changes concerning staging and modifications of the recommendations of therapy and follow-up...
  33. ncbi request reprint Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 10:4959-70. 2004
    ..Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-alpha...
  34. ncbi request reprint Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    J Natl Cancer Inst 97:1143-53. 2005
    ..We focused on plasmacytoid predendritic cells (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro...
  35. ncbi request reprint Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells
    Lucie Heinzerling
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Blood 106:2287-94. 2005
    ..All patients demonstrated an increased antimeasles antibody titer after therapy. The data demonstrate that CTCLs are promising targets for an MV-based oncolytic therapy...
  36. ncbi request reprint Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy
    Lucie Heinzerling
    Department of Dermatology, University of Zurich, CH 8091 Zurich, Switzerland
    Hum Gene Ther 16:35-48. 2005
    ..Serum levels revealed fluctuations. The results show that intratumoral injection of DNA produced some beneficial clinical effect. DNA encoding a cytokine may be useful as a therapeutic or adjuvant against various human cancers...
  37. ncbi request reprint CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich 8091, Switzerland
    Hum Pathol 36:1020-4. 2005
    ..MxA protein, representing the surrogate marker for lesional type I interferon activity, was expressed in 4 of 5 evaluated cases. Our findings further substantiate the putative pDC origin of CD4+CD56+ HNs...
  38. doi request reprint The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma
    Reinhard Dummer
    Skin Cancer Centre, Dept of Dermatology, University Hospital of Zurich, Switzerland
    Swiss Med Wkly 146:w14279. 2016
    ..Recent data on surgical and medical treatments from randomised trials necessitated modification of the treatment and follow-up recommendations...
  39. doi request reprint Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
    Simone M Goldinger
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland Electronic address
    Eur J Cancer 50:406-10. 2014
    ..This clinical investigation encourages further studies in prospective clinical trials to define the optimal treatment schedule for the MAPK pathway inhibition and should be accompanied by molecular monitoring using repeated biopsies...
  40. doi request reprint Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching
    Daniel S Widmer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Invest Dermatol 133:2436-43. 2013
    ..Thus, exposure of proliferative melanoma cells to hypoxic microenvironments is sufficient, in a HIF1α-dependent manner, to downregulate melanocytic marker expression and increase their invasive potential. ..
  41. ncbi request reprint S-100B and FDG-PET/CT in therapy response assessment of melanoma patients
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 215:192-201. 2007
    ..To compare the value of the tumor marker S-100B protein and fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in patients treated for melanoma metastases...
  42. doi request reprint Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Raemistr 100, 8091, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 35:1786-95. 2008
    ..This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in chemotherapy response assessment of stage IV melanoma patients...
  43. ncbi request reprint Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Arch Dermatol 139:1325-32. 2003
    ..It enhances innate and acquired immune responses via endogenous cytokine production and has proven efficacious in clearing superficial basal cell carcinoma (sBCC)...
  44. doi request reprint Aldara activates TLR7-independent immune defence
    Anne Walter
    Department of Oncology, University Hospital Zurich, Wagistrasse 14, 8952 Schlieren, Switzerland
    Nat Commun 4:1560. 2013
    ..Although it remains to be tested, it is possible that imiquimod-independent effects also contribute to the therapeutic efficacy of Aldara...
  45. ncbi request reprint Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients
    Karin Murer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Melanoma Res 14:257-62. 2004
    ..0038). This could not be shown for any of the markers tested by FACS. Our results suggest that the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival...
  46. ncbi request reprint Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Blood 103:1796-8. 2004
    ..Together with the expression of IL-10, HLA-G might be one of the factors accounting for the evasion of immunosurveillance, thus contributing to aggressive phenotype of these lymphoma entities...
  47. doi request reprint Melanoma after laser therapy of pigmented lesions--circumstances and outcome
    Marie C Zipser
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
    Eur J Dermatol 20:334-8. 2010
    ..A careful examination of all pigmented lesions using surface microscopy and representative biopsies in combination with a close follow-up is recommended...
  48. pmc RASopathic skin eruptions during vemurafenib therapy
    Jeannine D Rinderknecht
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    PLoS ONE 8:e58721. 2013
    ..Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions...
  49. doi request reprint Systematic classification of melanoma cells by phenotype-specific gene expression mapping
    Daniel S Widmer
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 25:343-53. 2012
    ..These findings reinforce the concept that a two-state system, as described by the phenotype switching model, underlies melanoma progression...
  50. ncbi request reprint Expression of melanoma-associated antigens in melanoma cell cultures
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 14:491-7. 2005
    ..05-0.001). Elucidation of the MAA expression patterns and the kinetics within the same patient as well as during the course of the disease may help improve current and develop new immunotherapeutic strategies...
  51. pmc Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007
    ..Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads...
  52. doi request reprint Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate
    Gunther F L Hofbauer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Melanoma Res 18:104-11. 2008
    ..Local GM-CSF expression could be induced. In summary, ALVAC GM-CSF and ALVAC IL-2 injections are safe and can mediate local biologic and immunologic effects...
  53. pmc The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report
    Ossia M Eichhoff
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Melanoma Res 20:349-55. 2010
    ..These results highlight the likelihood that disease progression involves melanoma cells retaining the capacity to regulate the expression of metastatic potential critical factors according to changing microenvironmental conditions...
  54. pmc Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients
    Alessandra Curioni-Fontecedro
    Division of Internal Medicine and Clinic of Oncology, University Hospital, Zurich, Switzerland
    PLoS ONE 6:e21418. 2011
    ..01). Our results suggest that the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary melanoma is a potent predictor of sentinel lymph node metastasis...
  55. doi request reprint Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3
    Laurence Feldmeyer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland Electronic address
    J Am Acad Dermatol 69:530-6. 2013
    ..Ultraviolet (UV) B radiation increases serum 25-hydroxyvitamin-D3 [25(OH)D], but the influence of UVA1 and UVA/narrowband UVB (UVBnb) phototherapy on serum vitamin D is unknown...
  56. doi request reprint Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system
    Benedetta Belloni
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Clin Pathol 66:124-35. 2013
    ..However, molecular analysis is impaired by the cross linking properties of formalin. The PAXgene tissue system (PreAnalytix, Switzerland) is a new formalin-free tissue collection device...
  57. ncbi request reprint Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors
    Michel Gilliet
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Arch Dermatol 140:1490-5. 2004
    ..It has been proposed that the innate immune system plays a central role in driving the autoimmune T-cell cascade leading to psoriasis; however, there is no direct evidence for this...
  58. ncbi request reprint Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma
    Antonio Cozzio
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Leuk Lymphoma 47:865-9. 2006
    ..All other patients remained free of disease. Thus, intra-lesional IFNalpha2a may represent a valuable alternative to surgery and radiotherapy as first-line treatment of pcMZL...
  59. ncbi request reprint Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression
    Chunlei Zhang
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Hum Pathol 38:995-1002. 2007
    ..Thus, cutaneous T-cell lymphoma cells show changes in oncogene and tumor suppressor gene expression that increase proliferation...
  60. ncbi request reprint Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Int J Cancer 121:1764-70. 2007
    ..005). This suggests that BMI-1 mediated repression of p16(ink4a) may contribute to an increased aggressive behavior of stem cell-like melanoma cells...
  61. doi request reprint Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate
    Beda Mühleisen
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Histopathology 55:67-76. 2009
    ..The aim was to determine whether qualitative and quantitative differences in perineoplastic inflammation in OTRs contribute to the increased carcinogenesis...
  62. doi request reprint Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas
    Anne Walter
    Laboratory of Tumor Immunology, Department of Oncology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 16:3562-70. 2010
    ..To find an explanation for the selective immunosurveillance of SCC, we investigated the expression of cancer-testis (CT) antigens and MHC class I (MHC-I) and the infiltration by immune cells in BCC and SCC...
  63. doi request reprint Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL
    Sima Rozati
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 22:2020-31. 2016
    ..Here, we explore the synergistic antiproliferative effects of romidepsin, an HDAC inhibitor, and azacitidine, a demethylating agent, combination in CTCL...
  64. doi request reprint Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth
    Gianluca Civenni
    Institute of Anatomy and Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
    Cancer Res 71:3098-109. 2011
    ....
  65. ncbi request reprint Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand
    Jörg Willers
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 9:2744-54. 2003
    ..Proliferation and apoptosis of cultured cells were measured by 5-bromo-2-desoxyuridine and propidium iodine incorporation...
  66. pmc Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients
    Natko Nuber
    Department of Oncology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 107:15187-92. 2010
    ..This study shows that CT7 can induce specific cellular immunity in melanoma patients. Based on these findings, CT7 will be further explored as a potential vaccine for melanoma immunotherapy...
  67. ncbi request reprint Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures
    Gunther F L Hofbauer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 211:318-24. 2005
    ..Apoptotic pathway aberrations are reported as important tumor progression factors in melanoma...
  68. ncbi request reprint Cutaneous malignant lymphomas: update 2006
    Gunter Burg
    Dept of Dermatology, University Hospital, Zurich, Switzerland
    J Dtsch Dermatol Ges 4:914-33. 2006
    ..Besides the classical options for therapy, there are new and "experimental" strategies, the efficacy of which has to be studied in clinical trials...
  69. ncbi request reprint Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 34:1366-75. 2007
    ..To evaluate the usefulness of PET/CT in melanoma patients with an elevated serum S-100B tumour marker level...
  70. pmc Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients
    Simone M Goldinger
    Dermatology and Pathology Departments, University Hospital of Zurich, Zurich, Switzerland
    Eur J Immunol 42:3049-61. 2012
    ..We conclude that the simultaneous use of both Imiquimod and CpG-ODN induced combined memory and effector CD8(+) T-cell responses...
  71. ncbi request reprint Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis
    Jörg Willers
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Exp Dermatol 14:543-50. 2005
    ..Moreover tyrosinase peptide antigens might be used as key tools in studying the boundaries between self-tolerance and autoimmunity phenomena...
  72. ncbi request reprint Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness
    Christian D Mnich
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Melanoma Res 17:131-6. 2007
    ..We hypothesize that the observed decrease in transforming growth factor beta signalling in thicker primary melanomas is due to the increased production of signalling inhibitors...
  73. pmc Tumor cell plasticity and angiogenesis in human melanomas
    Daniela Mihic-Probst
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 7:e33571. 2012
    ..0001). We suggest that the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically contribute to blood vessel formation...
  74. ncbi request reprint Extracutaneous transformation into a high-grade lymphoma: a potential pitfall in the management of patients with Sézary syndrome
    Sonja Michaelis
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Int J Dermatol 45:277-9. 2006
    ..Transformation into a high-grade lymphoma in cutaneous T-cell lymphoma (CTCL) occurs in approximately 25% of cases and is associated with an aggressive clinical course...
  75. ncbi request reprint Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein
    Mirjam Beyeler
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 213:187-91. 2006
    ..Early detection of melanoma recurrence is essential for the patient's prognosis. The serum S100 level may be a useful tool to detect relapse early...
  76. ncbi request reprint Weight of decision-making impairs clinical assessment of melanocytic lesions
    Tamara Gächter
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    J Cutan Med Surg 11:9-18. 2007
    ..We studied the weight of decision-making on clinical assessment of melanocytic lesions judging benign, atypical, and malignant lesions; common mistakes; and total removal rates, comparing dermatologists with nondermatologists...
  77. ncbi request reprint High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases
    Klaus Strobel
    Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Raemistr 100, 8091 Zurich, Switzerland
    Radiology 244:566-74. 2007
    ....
  78. doi request reprint Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography
    Patrick A Oberholzer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 217:351-5. 2008
    ..Baseline staging is important in all melanoma types, including melanoma with unknown primary site (MUP). Staging includes different examination strategies, each with different accuracy...
  79. doi request reprint Novel MITF targets identified using a two-step DNA microarray strategy
    Keith S Hoek
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 21:665-76. 2008
    ..Many of these new targets have known relevance to pigmentation and melanoma biology, and further emphasize the critical role of MITF in these processes...
  80. doi request reprint A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
    Marie C Zipser
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 24:326-33. 2011
    ..This suggests that while current therapeutic strategies target proliferative melanoma cells, future approaches should also account for the invasive phenotype population...
  81. ncbi request reprint HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Blood 99:609-17. 2002
    ..001). HLA-G up-regulation together with IL-10 expression in CL might additionally contribute to the evasion of immunosurveillance and facilitate the transition from low- to high-grade lymphomas...
  82. doi request reprint Evaluation of lymphangiogenic markers in Sézary syndrome
    Maria B Karpova
    Department of Dermatology, University of Zurich, Zurich, Switzerland
    Leuk Lymphoma 52:491-501. 2011
    ..We show for the first time a non-vascular pattern of VEGF-C and VEGFR-3, i.e. their epidermal expression in erythrodermic CTCLs, suggesting their role in lymphocyte trafficking to the skin...
  83. doi request reprint Id2 suppression of p15 counters TGF-beta-mediated growth inhibition of melanoma cells
    Natalie C Schlegel
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 22:445-53. 2009
    ..We conclude that transition to increased aggressiveness in melanoma cells requires Id2 upregulation to suppress TGF-beta induction of p15(Ink4b) and thus help to circumvent TGF-beta-mediated inhibition of proliferation...
  84. ncbi request reprint Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides
    Reinhard Dummer
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Dermatology 207:116-8. 2003
    ..However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months...
  85. ncbi request reprint Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimod
    Maja Wuest
    Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich, Switzerland
    Arch Dermatol Res 299:493-8. 2007
    ..Via induction of Notch signaling imiquimod may exert tumor suppressor function, which together with its proinflammatory properties results in tumor regression...
  86. pmc Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro
    Alessandra Curioni Fontecedro
    Faculty of Mathematics and Natural Sciences, Institute of Molecular Life Sciences, University of Zurich, and Department of Dermatology, University Hospital of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Virol J 7:175. 2010
    ..Most trans-complementing studies involved transgene expressions from strong ubiquitous promoters, and thereby relied entirely on the cancer cell specificity of the CRAd vector...
  87. ncbi request reprint Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2
    Beate Zagrodnik
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Cancer 98:2708-14. 2003
    ..In the current article, the authors report recurrence rates among patients with BCC after superficial radiotherapy as well as Bcl-2 and p53 expression levels stratified by BCC subtype...
  88. ncbi request reprint The anti-MAGE antibody B57 as a diagnostic marker in melanocytic lesions
    Dmitry V Kazakov
    Unit of Dermatopathology, Department of Dermatology, University Hospital, Zurich, Switzerland
    Am J Dermatopathol 26:102-7. 2004
    ....
  89. ncbi request reprint Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer
    Andreas Trojan
    Department of Oncology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Lung Cancer 44:143-7. 2004
    ..Our results indicate that CD8+ T cells infiltrating the tumor cell nests may be inadequately activated and thus incapable of mounting an effective anti-tumor immune response...
  90. doi request reprint In vivo switching of human melanoma cells between proliferative and invasive states
    Keith S Hoek
    Department of Dermatology, University Hospital of Zurich, Switzerland
    Cancer Res 68:650-6. 2008
    ..We present a new model for melanoma progression that accounts for transcription signature plasticity and provides a more rational context for explaining observed melanoma biology...
  91. doi request reprint Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fun
    Philippa Golling
    Department of Dermatology, Cutaneous Lymphoma Study Group, University Hospital, Zurich, Switzerland
    Leuk Lymphoma 49:1094-103. 2008
    ..Surgical excision or radiotherapy is highly effective in pcMZL and pcFCL...
  92. doi request reprint Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching
    Ossia M Eichhoff
    Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Pigment Cell Melanoma Res 24:631-42. 2011
    ..Our data show that melanoma cell phenotype switching behaviour is regulated by differential LEF1/TCF4 activity...
  93. ncbi request reprint [Cutaneous lymphoma]
    M Beyeler
    Dermatologische Klinik, Universitatsspital Zurich
    Hautarzt 55:1005-16; quiz 1017. 2004
    ..Therapy is based on the stage of the disease. Since cure is not possible, the aim of treatment is to control the disease and reduce symptoms. A variety of new and promising therapeutic modalities have been introduced in recent years...
  94. ncbi request reprint Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides?
    Reinhard Dummer
    Department of Dermatology, University Hospital, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Arch Dermatol 138:199-203. 2002
    ..To evaluate the clinical and prognostic features in primary cutaneous CD8+ T-cell lymphomas, which are rare and considered to be aggressive cutaneous lymphoproliferative disorders...
  95. ncbi request reprint Immunomodulators in the treatment of cutaneous lymphomas
    Reinhard Dummer
    Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
    Expert Opin Biol Ther 2:279-86. 2002
    ..New treatment approaches include fusion toxins and chimeric monoclonal antibodies (mAbs) such as rituximab for CBCLs. The identification of tumour antigens in CTCLs renders these diseases susceptible for vaccination approaches...
  96. ncbi request reprint High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma
    Gunther F L Hofbauer
    Department of Dermatology, University Hospital Zurich, Switzerland
    J Immunother 27:73-8. 2004
    ..However, no statistically significant correlation between loss of these antigens in individual primary tumors and negative impact on overall survival was found in our cohort...
  97. doi request reprint [Current therapy of carcinoma of the skin]
    Reinhard Dummer
    Dermatologische Klinik, Universitatsspital Zurich, Gloriastrasse, Zurich
    Ther Umsch 67:447-52. 2010
    ..We recommend according international guidelines that these patients are treated in the context of clinical trials in a melanoma reference center...
  98. ncbi request reprint Immunotherapy for nonmelanoma skin cancer: does it have a future?
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Switzerland
    Cancer 94:477-85. 2002
    ....
  99. ncbi request reprint Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations
    Ralf Geertsen
    Department of Dermatology, University Hospital, Zurich, Switzerland
    Int J Cancer 99:82-7. 2002
    ..We could document the occurrence of selective HLA-A2 deficiencies in cultured advanced-stage melanoma metastases and identify their molecular causes as genomic alterations within the HLA-A gene locus...
  100. ncbi request reprint Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technology
    Andreas Trojan
    Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
    J Immunother 25:264-8. 2002
    ..Our study indicates that quantitative polymerase chain reaction may be a supplement to chromium-release assay for monitoring in vitro expanded CTL precursor reactivity...
  101. ncbi request reprint Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells
    Chun Lei Zhang
    Department of Dermatology, University Hospital of Zurich, CH 8091 Zurich, Switzerland
    J Pathol 200:249-54. 2003
    ..Overexpression of Mcl-1 and synthesis of non-functional Bax may be responsible for the resistance of CTCL cells to the anti-cancer drugs chlorambucil and sulindac...